Quantifying how proteins in microbe and host interact
Antimicrobial resistance is a growing problem around the world. When microbes such as bacteria, viruses, parasites and fungi stop responding to antimicrobial medicines, most researchers respond by working to develop new vaccines. However, when host proteins bind to bacterial proteins, that binding masks some dominant antigenic sites on the pathogen. Because of this, traditional vaccines have seen poor antibody responses.
In a recent published in the journal ͵͵ & Cellular Proteomics, researchers at Lund University used affinity purification combined with quantitative mass spectrometry, or AP-MS, techniques to investigate if these bacteria and host protein–protein interaction networks could compromise the development of protective antibody responses; they used Streptococcus pyogenes, a bacteria that causes infections in humans,as a model system.
was the corresponding author of this study. “To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” he said.
Streptococcus pyogenesbelongs to Group A Streptococcus, or GAS, which affects about 18 million people annually, and claims over 500,000 lives, so an urgent need exists for a vaccine against GAS.
In , Malmström’s lab has shown that GAS forms extensive protein interaction networks with human proteins, so they wanted to analyze the association between the antigen-specific antibody responses and the host protein–bacterial protein interactions. They also wanted to understand if antigen-specific antibody responses could affect these protein networks to understand antibody repertoire (the entire set of antibodies produced in an individual), ultimately aiding the development of effective vaccines against GAS.
In this study, the researchers immunized mice with the conserved M1 protein from GAS and showed that mouse plasma protein forms similar protein networks with the bacterial M1 protein as those seen in humans. Using AP-MS, they quantified the competition among antibodies and protein interaction networks.
While the team found that the antigen targeted by the anti-M1 antibodies affected sites outside the protein interaction surfaces and could not outcompete these interactions, they also discovered in this study that regions in bacterial proteins within protein-interaction interfaces are more challenging to develop antibodies against, highlighting the need to quantify and assess these interactions.
Several bacterial pathogens use their surface proteins to interact with the host proteins to dodge the immune system and mask their dominant epitopes.
The experimental strategy developed in this study can measure the level of competition between antibodies and host plasma proteins at the same bacterial sites, thereby dictating the course of host immune responses. This method could be broadly applicable to any type of bacterial protein.
“I think that the most efficient way forward would be to build networks of scientists with different research skills and meet around the same problem,” Malmström said.
Read more about this group’s research .
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.
Computational and biophysical approaches to disordered proteins
Rohit Pappu will receive the 2025 DeLano Award for Computational Biosciences at the ASBMB Annual Meeting, April 12-15 in Chicago.